Marker Therapeutics (FRA:GX1) Tax Provision : €0.00 Mil (TTM As of Dec. 2024)

View and export this data going back to . Start your Free Trial

What is Marker Therapeutics Tax Provision?

Marker Therapeutics's tax provision for the three months ended in Dec. 2024 was €0.00 Mil. Its tax provision for the trailing twelve months (TTM) ended in Dec. 2024 was €0.00 Mil.

Marker Therapeutics Tax Provision Historical Data

The historical data trend for Marker Therapeutics's Tax Provision can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Marker Therapeutics Tax Provision Chart

Marker Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Tax Provision

Get a 7-Day Free Trial

-0.05

Marker Therapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Tax Provision	Get a 7-Day Free Trial															-	-	-	-	-

Marker Therapeutics Tax Provision Calculation

Tax to be paid.

Tax Provision for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

Marker Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Marker Therapeutics Inc (FRA:GX1) » Definitions » Tax Provision

Comparable Companies

Traded in Other Exchanges

MRKR:USA

Address

2450 Holcombe Boulevard, Suite e BCM-A, MS: BCM251, Houston, TX, USA, 77021

Website

https://www.markertherapeutics.com

Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets.

Marker Therapeutics Headlines

No Headlines